Key Highlights
- Tracey Lodie, PhD, joins GRO Biosciences as Chief Development Officer, bringing over 20 years of experience in the biopharmaceutical industry.
- Lodie’s background includes significant roles at Quell Therapeutics, Gamida Cell, and Blue Rock Therapeutics, among others.
- GRO Biosciences is advancing its unique Genomically Recoded Organism (GRO) platform to develop innovative protein therapeutics for autoimmune and metabolic diseases.
Source: Business Wire
Notable Quotes
- “Throughout my career, I have been passionate about bringing new therapeutics to patients, particularly those suffering from autoimmune disease and immunological disorders. GRObio’s unique GRO platform enables direct modulation of complex processes like immune responses, and I look forward to working with GRObio’s team of innovators to translate our demonstrated preclinical efficacy in animals to patients,” – Tracey Lodie, PhD, Chief Development Officer at GRO Biosciences
- “We are delighted to add Tracey to our executive team. Her world-class experience in immunology, clinical translation, development, and commercialization will be instrumental as we advance our programs into the clinic,” – Daniel J. Mandell, PhD, Chief Executive Officer at GRO Biosciences
- “GRO Biosciences has built a powerful platform that is now delivering exciting programs to reverse autoimmune disease and eliminate immunogenicity for patients in need of safer, more effective therapies. Dr. Lodie’s addition to the executive team brings critical management expertise to support the continued evolution of GRO Biosciences into a clinical-stage organization.” – Juergen Eckhardt, MD, Head of Leaps by Bayer and Head of Pharma Business Development at Bayer
SoHC's Take
GRO Biosciences is at a pivotal juncture, enhancing its leadership to steer its innovative platform towards clinical successes. The recruitment of Dr. Tracey Lodie underscores the company’s commitment to pioneering advancements in protein therapeutics. With a proven track record in immunology and biopharmaceutical development, Dr. Lodie’s expertise is poised to accelerate GRObio’s journey from research to real-world impact. Her appointment signals a strategic move to harness her extensive experience in translating scientific discoveries into tangible treatments, especially for autoimmune diseases and immunological disorders. This leadership expansion is a clear indicator of GRObio’s dedication to advancing its cutting-edge therapies into the clinic, offering new hope for patients with complex medical needs.
